PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT?... by L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko

“…Many years of practice and experience of warfarin use, unfortunately, did not lead to wider and more efficient use of anticoagulation therapy. New oral anticoagulants devoid of drawbacks of warfarin, which prevented its prescription and long-term use, have appeared in the past few years. …”
Get full text

PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT?... by L. Y. Koroleva, I. V. Kolesnichenko, V. P. Nosov, I. I. Gritsenko, E. S. Timoschenko

“…Many years of practice and experience of warfarin use, unfortunately, did not lead to wider and more efficient use of anticoagulation therapy. New oral anticoagulants devoid of drawbacks of warfarin, which prevented its prescription and long-term use, have appeared in the past few years. …”
Get full text

Systemic Thrombolytic Therapy for Ischemic Stroke in the Course of Anticoagulants by L. Kh.-B. Akhmatkhanova, G. R. Ramazanov, E. V. Klychnikova, R. Sh. Muslimov, M. V. Parkhomenko

“…Sklifosovsky Research Institute for Emergency Medicine in reperfusion therapy for ischemic stroke in a patient taking oral anticoagulant.…”
Get full text

Physician’s Adherence to Clinical Guidelines for in-Hospital Anticoagulant Prescribing by A. A. Chernov, E. V. Kleymenova, D. A. Sychev, L. P. Yashina, M. D. Nigmatkulova, V. A. Otdelenov, S. A. Payushchik

“…ACs were prescribed for 43 (86%) AF patients, including warfarin (39.5%), direct oral anticoagulants (DOAC) (46.5%) and low-molecular weight heparin (LMWH) (14%). …”
Get full text

Esophagitis Dissecans Superficialis in a Frail Older Patient: Questioning Its Benign Nature by Donna Erven, Tom J. G. Gevers, Bart Spaetgens, Renée A. G. Brüggemann

Subjects: “…direct oral anticoagulants (DOACs)…”
Get full text

Prevention and treatment of thrombosis in cancer and oncohematological patients by O. V. Somonova, A. L. Elizarova, T. V. Davydova

Subjects: Get full text

Risk Controlling of Gastrointestinal Bleeding in Comorbid Patients with Cardiovascular Diseases by O. Yu. Chizhova, L. N. Belousova, I. G. Bakulin

Subjects: “…non-vitamin k antagonist oral anticoagulants…”
Get full text

Off-Label Medicines Use: Complex Problem of Modern Clinical Practice by S. R. Gilyarevskiy

Subjects: Get full text

Clinical application of clinical decision support systems in the management of patients with atrial fibrillation by A. V. Ponomarenko, A. D. Gavrilko, A. A. Gartung, M. S. Poliakova, A. A. Oganesyan, K. S. Benimetskaya, D. V. Losik, S. V. Shalaev

Subjects: Get full text

Changes in anticoagulant prescription in a general hospital in 2008-2018 by E. B. Kleymenova, V. A. Otdelenov, M. D. Nigmatkulova, S. A. Payushchik, A. A. Chernov, O. D. Konova, L. P. Yashina, A. M. Cherkashov, D. A. Sychev

“…According to retrospective retrieval from electronic health records, total 17,129 patients received anticoagulants from 2008 to 2018. Formal appropriateness of oral anticoagulants (OАС) prescriptions for 6,638 patients with atrial fibrillation (AF) was analyzed with CHA2-DS2-VASc score.Results. …”
Get full text

Is anticoagulant therapy necessary after hospitalization with COVID-19 pneumonia? by P. A. Davtyan, R. M. Gumerov, Sh. Z. Zagidullin, A. V. Samorodov, B. Cai, N. Sh. Zagidullin

“…In particular, some of them, including the Russian Ministry of Health guidelines recommend 30-45day anticoagulation using novel oral anticoagulants (dabigatran, rivaroxaban, apixaban), but other sources do not provide such recommendations. …”
Get full text

A Case of Anticoagulant-induced Spontaneous Intramural Intestinal Hematoma by Ho Joon Park, Gwang Ha Kim, Sang Kyu Park, Do Youn Park

“…Spontaneous intramural hematoma is a rare complication of oral anticoagulants, and its incidence is expected to increase because of the increasing number of elderly patients undergoing anticoagulant therapy. …”
Get full text

COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION by A. V. Rudakova, V. A. Parfenov

Subjects: Get full text

PRACTICAL ASPECTS OF APIXABAN USE IN CLINICAL PRACTICE: VIEW POINT OF CLINICAL PHARMACOLOGIST by D. A. Sychev, I. I. Sinitsina, G. Yu. Zakharova, M. I. Savel'eva, A. V. Ryabova, A. V. Kryukov, A. Yu. Yurovskii

Subjects: “…new oral anticoagulants…”
Get full text

PREVENTION OF STROKE IN ATRIAL FIBRILLATION: THE APPROACHES TO THE CHOICE OF ANTICOAGULANT, DEPENDING ON AGE by A. V. Ardashev, I. V. Zotova

“…Keywords: prevention of stroke, atrial fibrillation, cardiovascular disease, new oral anticoagulants.…”
Get full text

Elderly Patients with Atrial Fibrillation: Focus on Comorbidity and Safety of Anticoagulant Therapy by D. A. Napalkov, A. A. Sokolova

“…The use of unreasonably low doses of oral anticoagulants in elderly patients is debated. …”
Get full text

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology by S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova

“…A recently published article [1 ] on the problems of anticoagulant therapy in patients with frailty syndrome contains two statements which highlight ri-varoxaban among other non-vitamin K antagonist oral anticoagulants (NOAC): 1) none of the randomized controlled trials (RCTs) with NOAC (except for two RCTs with rivaroxaban - EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail patients; 2) one of the studies of real clinical practice showed that only therapy with rivaroxaban (out of three NOAC) in comparison to warfarin reduced the risk of stroke/systemic embolism and ischemic stroke in frail elderly patients with atrial fibrillation after 2 years of observation. …”
Get full text

Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology by Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova

“…A recently published article (Rational Pharmacotherapy in Cardiology 2018;6:908-16) on the problems of anticoagulant therapy in patients with frailty syndrome contains two statements which highlight rivaroxaban among other non-vitamin K antagonist oral anticoagulants (NOAC): 1) none of the randomized controlled trials (RCTs) with NOAC (except for two RCTs with rivaroxaban – EINSTEIN-DVT and EINSTEIN-PE) contained data on the participation of frail patients; 2) one of the studies of real clinical practice showed that only therapy with rivaroxaban (out of three NOAC) in comparison to warfarin reduced the risk of stroke / systemic embolism and ischemic stroke in frail elderly patients with atrial fibrillation after 2 years of observation. …”
Get full text

Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients by A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin

Subjects: Get full text

PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION by A. V. Rudakova

Subjects: Get full text